- Home
- CHRS vs DLNG Comparison
CHRS vs DLNG Comparison
Compare CHRS & DLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- DLNG
- Stock Information
- Founded
- CHRS 2010
- DLNG 2013
- Country
- CHRS United States
- DLNG Greece
- Employees
- CHRS N/A
- DLNG N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- DLNG Marine Transportation
- Sector
- CHRS Health Care
- DLNG Consumer Discretionary
- Exchange
- CHRS Nasdaq
- DLNG Nasdaq
- Market Cap
- CHRS 134.4M
- DLNG 157.7M
- IPO Year
- CHRS 2014
- DLNG 2013
- Fundamental
- Price
- CHRS $1.07
- DLNG $4.14
- Analyst Decision
- CHRS Strong Buy
- DLNG
- Analyst Count
- CHRS 4
- DLNG 0
- Target Price
- CHRS $5.38
- DLNG N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- DLNG 88.4K
- Earning Date
- CHRS 03-12-2025
- DLNG 03-26-2025
- Dividend Yield
- CHRS N/A
- DLNG 2.37%
- EPS Growth
- CHRS N/A
- DLNG 42.98
- EPS
- CHRS N/A
- DLNG 0.99
- Revenue
- CHRS $304,340,000.00
- DLNG $151,689,000.00
- Revenue This Year
- CHRS $2.07
- DLNG N/A
- Revenue Next Year
- CHRS N/A
- DLNG N/A
- P/E Ratio
- CHRS N/A
- DLNG $4.19
- Revenue Growth
- CHRS 44.19
- DLNG N/A
- 52 Week Low
- CHRS $0.66
- DLNG $2.27
- 52 Week High
- CHRS $2.65
- DLNG $5.65
- Technical
- Relative Strength Index (RSI)
- CHRS 39.03
- DLNG 28.85
- Support Level
- CHRS $1.06
- DLNG $4.21
- Resistance Level
- CHRS $1.16
- DLNG $4.40
- Average True Range (ATR)
- CHRS 0.08
- DLNG 0.23
- MACD
- CHRS 0.00
- DLNG -0.04
- Stochastic Oscillator
- CHRS 5.56
- DLNG 4.44
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About DLNG Dynagas LNG Partners LP Common Units
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.